{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:20:52Z","timestamp":1787746852319,"version":"build-2784847793"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2023YFS0257"],"award-info":[{"award-number":["2023YFS0257"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05360-5","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:43:23Z","timestamp":1787744603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent radiosensitising regimens for bladder-preserving radiotherapy in non-metastatic muscle-invasive bladder cancer: a systematic review and structured evidence synthesis with exploratory network meta-analysis"],"prefix":"10.1007","author":[{"given":"Yucong","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"5360_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carrion A et al (2025) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol 87:582\u2013600. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019","journal-title":"Eur Urol"},{"key":"5360_CR2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.eururo.2026.01.029","volume":"89","author":"S Gupta","year":"2026","unstructured":"Gupta S, Li R, Hensley PJ et al (2026) Optimal management of muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. Eur Urol 89:500\u2013511. https:\/\/doi.org\/10.1016\/j.eururo.2026.01.029","journal-title":"Eur Urol"},{"key":"5360_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol 198:552\u2013559. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086","journal-title":"J Urol"},{"key":"5360_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5","journal-title":"Lancet Oncol"},{"key":"5360_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.euf.2024.11.003","volume":"11","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Miszczyk M et al (2025) Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: a systematic review and meta-analysis of matched cohort studies. Eur Urol Focus 11:374\u2013385. https:\/\/doi.org\/10.1016\/j.euf.2024.11.003","journal-title":"Eur Urol Focus"},{"key":"5360_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.euo.2023.03.004","volume":"6","author":"R Kool","year":"2023","unstructured":"Kool R, Marcq G, Breau RH, Black PC, Shayegan B, Kim M, Busca I, Abdi H, Dawidek MT, Uy M, Fervaha G, Cury FL, Alimohamed NS, Izawa JI, Jeldres C, Rendon R, Siemens DR, Kulkarni GS, Kassouf W (2023) Radiation-based therapy for muscle-invasive bladder cancer: contemporary outcomes across tertiary centers. Eur Urol Oncol 6:597\u2013603. https:\/\/doi.org\/10.1016\/j.euo.2023.03.004","journal-title":"Eur Urol Oncol"},{"key":"5360_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijrobp.2024.08.036","volume":"121","author":"PP Avolio","year":"2025","unstructured":"Avolio PP, Kool R, Shayegan B et al (2025) Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 121:317\u2013324. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.036","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","volume":"61","author":"JA Efstathiou","year":"2012","unstructured":"Efstathiou JA, Spiegel DY, Shipley WU et al (2012) Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61:705\u2013711. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.010","journal-title":"Eur Urol"},{"key":"5360_CR9","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols. J Clin Oncol 32:3801\u20133809. https:\/\/doi.org\/10.1200\/JCO.2014.57.5548","journal-title":"J Clin Oncol"},{"key":"5360_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH et al (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 71:952\u2013960. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.020","journal-title":"Eur Urol"},{"key":"5360_CR11","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","volume":"35","author":"GS Kulkarni","year":"2017","unstructured":"Kulkarni GS, Hermanns T, Wei Y et al (2017) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 35:2299\u20132305. https:\/\/doi.org\/10.1200\/JCO.2016.69.2327","journal-title":"J Clin Oncol"},{"key":"5360_CR12","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou JA, Bae K, Shipley WU et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89\u201303, 95\u201306, 97\u201306, 99\u201306. J Clin Oncol 27:4055\u20134061. https:\/\/doi.org\/10.1200\/JCO.2008.19.5776","journal-title":"J Clin Oncol"},{"key":"5360_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.6004\/jnccn.2013.0116","volume":"11","author":"RC Chen","year":"2013","unstructured":"Chen RC, Shipley WU, Efstathiou JA, Zietman AL (2013) Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw 11:952\u2013960. https:\/\/doi.org\/10.6004\/jnccn.2013.0116","journal-title":"J Natl Compr Canc Netw"},{"key":"5360_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1200\/JCO.19.02959","volume":"38","author":"DM Jiang","year":"2020","unstructured":"Jiang DM, Chung P, Kulkarni GS, Sridhar SS (2020) Trimodality therapy for muscle-invasive bladder cancer. J Clin Oncol 38:638\u2013645. https:\/\/doi.org\/10.1200\/JCO.19.02959","journal-title":"J Clin Oncol"},{"key":"5360_CR15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477\u20131488. https:\/\/doi.org\/10.1056\/NEJMoa1106106","journal-title":"N Engl J Med"},{"key":"5360_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","volume":"82","author":"E Hall","year":"2022","unstructured":"Hall E, Hussain SA, Porta N et al (2022) Chemoradiotherapy in muscle-invasive bladder cancer: 10-year follow-up of the phase 3 randomized controlled BC2001 trial. Eur Urol 82:273\u2013279. https:\/\/doi.org\/10.1016\/j.eururo.2022.04.017","journal-title":"Eur Urol"},{"key":"5360_CR17","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","volume":"28","author":"PJ Hoskin","year":"2010","unstructured":"Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28:4912\u20134918. https:\/\/doi.org\/10.1200\/JCO.2010.28.4950","journal-title":"J Clin Oncol"},{"key":"5360_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","volume":"110","author":"YP Song","year":"2021","unstructured":"Song YP, Mistry H, Irlam J et al (2021) Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON phase 3 randomized trial. Int J Radiat Oncol Biol Phys 110:1407\u20131415. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR19","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","volume":"14","author":"CM Coppin","year":"1996","unstructured":"Coppin CM, Gospodarowicz MK, James K et al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14:2901\u20132907. https:\/\/doi.org\/10.1200\/JCO.1996.14.11.2901","journal-title":"J Clin Oncol"},{"key":"5360_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"T Mitin","year":"2013","unstructured":"Mitin T, Hunt D, Shipley WU et al (2013) Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for muscle-invasive bladder cancer (RTOG 0233): a randomized multicentre phase 2 trial. Lancet Oncol 14:863\u2013872. https:\/\/doi.org\/10.1016\/S1470-2045(13)70255-9","journal-title":"Lancet Oncol"},{"key":"5360_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.18.00537","volume":"37","author":"JJ Coen","year":"2019","unstructured":"Coen JJ, Zhang P, Saylor PJ et al (2019) Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once-daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712. J Clin Oncol 37:44\u201351. https:\/\/doi.org\/10.1200\/JCO.18.00537","journal-title":"J Clin Oncol"},{"key":"5360_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijrobp.2024.08.007","volume":"121","author":"JJ Coen","year":"2025","unstructured":"Coen JJ, Rodgers JP, Saylor PJ et al (2025) Long-term results of bladder preservation with twice-daily radiation plus 5-fluorouracil\/cisplatin or daily radiation plus gemcitabine for muscle-invasive bladder cancer: updated report of NRG\/RTOG 0712. Int J Radiat Oncol Biol Phys 121:153\u2013161. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2026.111443","volume":"217","author":"M Michalet","year":"2026","unstructured":"Michalet M, Ronchin P, Reynaud T et al (2026) Radiotherapy with twice-weekly gemcitabine and cisplatin compared to cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial. Radiother Oncol 217:111443. https:\/\/doi.org\/10.1016\/j.radonc.2026.111443","journal-title":"Radiother Oncol"},{"key":"5360_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0360-3016(95)00136-M","volume":"33","author":"M Orsatti","year":"1995","unstructured":"Orsatti M, Curotto A, Canobbio L et al (1995) Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 33:173\u2013178. https:\/\/doi.org\/10.1016\/0360-3016(95)00136-M","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104557","volume":"205","author":"C Baudelin","year":"2025","unstructured":"Baudelin C, Sargos P, Dinart D et al (2025) Concomitant chemotherapy in trimodal treatment of patients with muscle-invasive bladder cancer: a systematic review of prospective trials. Crit Rev Oncol Hematol 205:104557. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104557","journal-title":"Crit Rev Oncol Hematol"},{"key":"5360_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3238\/arztebl.m2025.0014","volume":"122","author":"A Heidenreich","year":"2025","unstructured":"Heidenreich A, Bohmer D, Bolenz C, Borkowetz A, Rieger C, De Santis M (2025) New bladder preservation strategies in urothelial carcinoma of the bladder. Dtsch Arztebl Int 122:211\u2013218. https:\/\/doi.org\/10.3238\/arztebl.m2025.0014","journal-title":"Dtsch Arztebl Int"},{"key":"5360_CR27","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ijrobp.2016.11.056","volume":"97","author":"V Vashistha","year":"2017","unstructured":"Vashistha V, Wang H, Mazzone A et al (2017) Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 97:1002\u20131020. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.056","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","volume":"96","author":"KS Mak","year":"2016","unstructured":"Mak KS, Smith AB, Eidelman A et al (2016) Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 96:1028\u20131036. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.08.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clgc.2018.09.023","volume":"17","author":"TJ Royce","year":"2019","unstructured":"Royce TJ, Feldman AS, Mossanen M et al (2019) Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer. Clin Genitourin Cancer 17:23-31.e3. https:\/\/doi.org\/10.1016\/j.clgc.2018.09.023","journal-title":"Clin Genitourin Cancer"},{"key":"5360_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110038","volume":"190","author":"G Francolini","year":"2024","unstructured":"Francolini G, Ghoshal A, Caini S et al (2024) Quality of life after definitive treatment for bladder cancer: a systematic review and meta-analysis. Radiother Oncol 190:110038. https:\/\/doi.org\/10.1016\/j.radonc.2023.110038","journal-title":"Radiother Oncol"},{"key":"5360_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ucl.2015.01.003","volume":"42","author":"C Premo","year":"2015","unstructured":"Premo C, Apolo AB, Agarwal PK, Citrin DE (2015) Trimodality therapy in bladder cancer: who, what and when? Urol Clin North Am 42:169\u2013180. https:\/\/doi.org\/10.1016\/j.ucl.2015.01.003","journal-title":"Urol Clin North Am"},{"key":"5360_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"5360_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions. Ann Intern Med 162:777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"5360_CR34","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/1097-0142(19931001)72:7<2213::AID-CNCR2820720724>3.0.CO;2-3","volume":"72","author":"B Chauvet","year":"1993","unstructured":"Chauvet B, Brewer Y, Felix-Faure C, Davin JL, Vincent P, Reboul F (1993) Combined radiation therapy and cisplatin for locally advanced carcinoma of the urinary bladder. Cancer 72:2213\u20132218. https:\/\/doi.org\/10.1002\/1097-0142(19931001)72:7%3c2213::AID-CNCR2820720724%3e3.0.CO;2-3","journal-title":"Cancer"},{"key":"5360_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-G","volume":"25","author":"W Tester","year":"1993","unstructured":"Tester W, Porter A, Asbell S et al (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783\u2013790. https:\/\/doi.org\/10.1016\/0360-3016(93)90306-G","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","volume":"14","author":"W Tester","year":"1996","unstructured":"Tester W, Caplan R, Heaney J et al (1996) Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14:119\u2013126. https:\/\/doi.org\/10.1200\/JCO.1996.14.1.119","journal-title":"J Clin Oncol"},{"key":"5360_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","volume":"57","author":"MP Hagan","year":"2003","unstructured":"Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97\u201306: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV chemotherapy. Int J Radiat Oncol Biol Phys 57:665\u2013672. https:\/\/doi.org\/10.1016\/S0360-3016(03)00718-1","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.radonc.2006.09.001","volume":"81","author":"NK Gogna","year":"2006","unstructured":"Gogna NK, Matthews JHL, Turner SL et al (2006) Efficacy and tolerability of concurrent weekly low-dose cisplatin during radiation treatment of localised muscle-invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from TROG. Radiother Oncol 81:9\u201317. https:\/\/doi.org\/10.1016\/j.radonc.2006.09.001","journal-title":"Radiother Oncol"},{"key":"5360_CR39","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1200\/JCO.1993.11.11.2150","volume":"11","author":"M Housset","year":"1993","unstructured":"Housset M, Maulard C, Chretien Y et al (1993) Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 11:2150\u20132157. https:\/\/doi.org\/10.1200\/JCO.1993.11.11.2150","journal-title":"J Clin Oncol"},{"key":"5360_CR40","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0022-5347(01)62379-6","volume":"160","author":"AL Zietman","year":"1998","unstructured":"Zietman AL, Shipley WU, Kaufman DS et al (1998) A phase I\/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice-daily radiation followed by selective bladder preservation in operable patients with muscle-invading bladder cancer. J Urol 160:1673\u20131677. https:\/\/doi.org\/10.1016\/S0022-5347(01)62379-6","journal-title":"J Urol"},{"key":"5360_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"DS Kaufman","year":"2000","unstructured":"Kaufman DS, Winter KA, Shipley WU et al (2000) The initial results in muscle-invading bladder cancer of RTOG 95\u201306: transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy. Oncologist 5:471\u2013476. https:\/\/doi.org\/10.1634\/theoncologist.5-6-471","journal-title":"Oncologist"},{"key":"5360_CR42","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0360-3016(03)00124-X","volume":"56","author":"WC Chen","year":"2003","unstructured":"Chen WC, Liaw CC, Chuang CK et al (2003) Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56:726\u2013733. https:\/\/doi.org\/10.1016\/S0360-3016(03)00124-X","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR43","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.ijrobp.2007.01.054","volume":"68","author":"C Weiss","year":"2007","unstructured":"Weiss C, Engehausen DG, Krause FS et al (2007) Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68:1072\u20131080. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.01.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijrobp.2008.08.021","volume":"74","author":"KS Oh","year":"2009","unstructured":"Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM (2009) Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 74:511\u2013517. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.08.021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5360_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5430\/jst.v3n3p1","volume":"3","author":"D Osama","year":"2013","unstructured":"Osama D, Shalaby M, Aboziada M (2013) A feasibility study of transurethral resection followed by radiotherapy combined with concurrent twice-weekly gemcitabine in the treatment of invasive bladder carcinoma. J Solid Tumors 3(3):1\u20138. https:\/\/doi.org\/10.5430\/jst.v3n3p1","journal-title":"J Solid Tumors"},{"key":"5360_CR46","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/annonc\/mdu209","volume":"25","author":"M De Santis","year":"2014","unstructured":"De Santis M, Bachner M, Cerveny M et al (2014) Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and\/or in patients ineligible for surgery: a phase I trial. Ann Oncol 25:1789\u20131794. https:\/\/doi.org\/10.1093\/annonc\/mdu209","journal-title":"Ann Oncol"},{"key":"5360_CR47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ijrobp.2016.11.040","volume":"97","author":"C Thompson","year":"2017","unstructured":"Thompson C, Joseph N, Sanderson B et al (2017) Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 97:732\u2013739. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.040","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00066-007-1651-z","volume":"183","author":"A Muller","year":"2007","unstructured":"Muller A, Diestelhorst A, Kuhnt T et al (2007) Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther Onkol 183:177\u2013183. https:\/\/doi.org\/10.1007\/s00066-007-1651-z","journal-title":"Strahlenther Onkol"},{"key":"5360_CR49","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","volume":"73","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Winter KA, Shipley WU et al (2009) Phase I-II RTOG study (99\u201306) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy. Urology 73:833\u2013837. https:\/\/doi.org\/10.1016\/j.urology.2008.09.036","journal-title":"Urology"},{"key":"5360_CR50","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ijrobp.2013.11.016","volume":"88","author":"D Azria","year":"2014","unstructured":"Azria D, Riou O, Rebillard X et al (2014) Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial. Int J Radiat Oncol Biol Phys 88:853\u2013859. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.11.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5360_CR51","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jjco\/hyac095","volume":"52","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Matsumoto H, Misumi T et al (2022) The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for muscle-invasive bladder cancer: a single-arm phase II study. Jpn J Clin Oncol 52:1201\u20131207. https:\/\/doi.org\/10.1093\/jjco\/hyac095","journal-title":"Jpn J Clin Oncol"},{"key":"5360_CR52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/BLC-160090","volume":"3","author":"BG Bachir","year":"2017","unstructured":"Bachir BG, Souhami L, Mansure JJ et al (2017) Phase I clinical trial of everolimus combined with trimodality therapy in patients with muscle-invasive bladder cancer. Bladder Cancer Amsterdam Netherlands 3:105\u2013112. https:\/\/doi.org\/10.3233\/BLC-160090","journal-title":"Bladder Cancer Amsterdam Netherlands"},{"key":"5360_CR53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.juro.2018.10.007","volume":"201","author":"EE Fransen van de Putte","year":"2019","unstructured":"Fransen van de Putte EE, Pos FJ, Doodeman B et al (2019) Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer. J Urol 201:478\u2013485. https:\/\/doi.org\/10.1016\/j.juro.2018.10.007","journal-title":"J Urol"},{"key":"5360_CR54","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1038\/sj.bjc.6601852","volume":"90","author":"SA Hussain","year":"2004","unstructured":"Hussain SA, Stocken DD, Peake DR et al (2004) Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle-invasive bladder cancer. Br J Cancer 90:2106\u20132111. https:\/\/doi.org\/10.1038\/sj.bjc.6601852","journal-title":"Br J Cancer"},{"key":"5360_CR55","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1080\/02656736.2022.2109763","volume":"39","author":"O Riesterer","year":"2022","unstructured":"Riesterer O, Ademaj A, Puric E et al (2022) Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study. Int J Hyperthermia 39:1078\u20131087. https:\/\/doi.org\/10.1080\/02656736.2022.2109763","journal-title":"Int J Hyperthermia"},{"key":"5360_CR56","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.21608\/mjcu.2019.85229","volume":"87","author":"NSS El-Din","year":"2019","unstructured":"El-Din NSS, Barakat AF, Sheta MF, Radwan MH (2019) Three-dimensional conformal radiotherapy with concomitant boost and weekly cisplatin in muscle-invasive transitional cell bladder carcinoma. Med J Cairo Univ 87:4867\u20134875. https:\/\/doi.org\/10.21608\/mjcu.2019.85229","journal-title":"Med J Cairo Univ"},{"key":"5360_CR57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clgc.2022.07.007","volume":"21","author":"S Soltanzadeh","year":"2023","unstructured":"Soltanzadeh S, Saeedian A, Ghalehtaki R et al (2023) Assessment of tolerability, response and complications of concurrent chemoradiation with capecitabine and cisplatin in muscle-invasive bladder cancer: a single-arm study. Clin Genitourin Cancer 21:101\u2013105. https:\/\/doi.org\/10.1016\/j.clgc.2022.07.007","journal-title":"Clin Genitourin Cancer"},{"key":"5360_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.31557\/APJCP.2023.24.2.517","volume":"24","author":"AA Youssief Mohammed","year":"2023","unstructured":"Youssief Mohammed AA, Gamal DA, Abd Elzaher AR, Hasaballah A (2023) Trimodality therapy in which concurrent chemoradiation with concomitant boost in muscle-invasive TCC urinary bladder cancer. Asian Pac J Cancer Prev 24:517\u2013524. https:\/\/doi.org\/10.31557\/APJCP.2023.24.2.517","journal-title":"Asian Pac J Cancer Prev"},{"key":"5360_CR59","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","volume":"20","author":"C R\u00f6del","year":"2002","unstructured":"R\u00f6del C, Grabenbauer GG, K\u00fchn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061\u20133071. https:\/\/doi.org\/10.1200\/JCO.2002.11.027","journal-title":"J Clin Oncol"},{"issue":"1","key":"5360_CR60","first-page":"6","volume":"61","author":"MA Tunio","year":"2011","unstructured":"Tunio MA, Hashmi A, Rafi M, Qayyum A, Masood R (2011) Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation. J Pak Med Assoc 61(1):6\u201310","journal-title":"J Pak Med Assoc"},{"issue":"11","key":"5360_CR61","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/bco2.443","volume":"5","author":"L Mannion","year":"2024","unstructured":"Mannion L, Watson V, Mullassery V et al (2024) Treatment preferences of patients with muscle invasive bladder cancer: a discrete choice experiment. BJUI Compass 5(11):1173\u20131182. https:\/\/doi.org\/10.1002\/bco2.443","journal-title":"BJUI Compass"},{"key":"5360_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.urology.2025.08.013","volume":"206","author":"AB Smith","year":"2025","unstructured":"Smith AB, Gore JL, Chisolm S et al (2025) Muscle-invasive bladder cancer treatment selection in an emerging treatment era: a patient preference study. Urology 206:76\u201385. https:\/\/doi.org\/10.1016\/j.urology.2025.08.013","journal-title":"Urology"},{"key":"5360_CR63","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.2147\/PPA.S411751","volume":"17","author":"K King-Concialdi","year":"2023","unstructured":"King-Concialdi K, Beusterien K, Senglaub SS et al (2023) Patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma: a multi-country discrete choice experiment. Patient Prefer Adherence 17:2237\u20132248. https:\/\/doi.org\/10.2147\/PPA.S411751","journal-title":"Patient Prefer Adherence"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05360-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:43:24Z","timestamp":1787744604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05360-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":63,"alternative-id":["5360"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05360-5","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This systematic review used previously published aggregate data and involved no new recruitment of human participants, human tissue, individual-level patient data, or animal experiments.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}